Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiometabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SGLT2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SGLT2 Full-Length Membrane Preparation High purity (>90% by SDS-PAGE), Endotoxin <1EU/ug. Sequence Verified. |
View SGLT2 Products |
| Gene Delivery | SGLT2 Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction. HEK293 Expressed (Native Glycosylation). Sequence verified. |
View SGLT2 Products |
| Benchmark Ab | Anti-SGLT2 (Research Grade) Recombinant positive control for flow cytometry / IHC. Sequence Verified. |
View SGLT2 Products |
| Validator | SGLT2 siRNA Set For knockdown verification in cell-based assays. Sequence Verified. |
View SGLT2 Products |
| Related Target | SGLT1 (SLC5A1) Selectivity screening to avoid GI toxicity; crucial for dual-inhibitor screening. |
View SGLT1 Products |
| Related Target | SGLT3 (SLC5A4) Family member for cross-reactivity assessment. |
View SGLT3 Products |
| Related Target | GLP-1R Synergistic pathway target for obesity and NASH combinations. |
View GLP-1R Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (14 TM Domains) | High-titer Lentivirus for stable cell line generation to preserve native folding |
| Selectivity vs SGLT1 (SLC5A1) | Human/Mouse/Cyno SGLT1 & SGLT2 ortholog proteins available with >95% purity |
| Subfamily Off-Target Effects (SGLT1) – Clones | Sequence-verified SGLT1 clones available for rigorous counter-screening |
| Cross-species cyno/mouse eval | Ortholog proteins sequence verified by Mass Spec |
| Functional glucose uptake assay | Lentivirus stable cell lines with native glycosylation pattern (HEK293 Expressed) |
| Target engagement & background reduction | Sequence-verified siRNA for specificity confirmation and knockdown verification |
| Lack of Reliable Controls | Benchmark recombinant antibodies included for assay standardization |
Live SGLT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance & Compensatory Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for next-generation SGLT2 therapeutics has fundamentally shifted from traditional Type 2 Diabetes management to broad cardiovascular and renal protection. Major players are focusing on differentiated modalities including dual SGLT1/2 inhibitors, tissue-specific biologics, and combination therapies for NASH, obesity, and refractory heart failure. As first-generation therapies (Empagliflozin, Dapagliflozin) dominate the diabetes and heart failure markets, the next wave of R&D is targeting refractory patient populations and renal-specific delivery mechanisms to minimize off-target GI effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Boehringer Ingelheim, AstraZeneca, J&J | T2D, Heart Failure, CKD | Selectivity Assay (SGLT2 vs SGLT1) with high-purity ortholog proteins; Cell-based uptake assay (Lentivirus stable lines) |
| Dual SGLT1/2 Inhibitor | Lexicon Pharmaceuticals | T2D with SGLT2i intolerance, Heart Failure | Dual Target Engagement (Need Both SGLT1 & SGLT2 Proteins/Cell Lines) |
| Next-Gen Biologic | Research Institutions | Tissue-specific modulation | Cell-based Internalization (Lentivirus Stable Cell Lines) |
| Combination (w/ GLP-1) | Various Biopharma | Obesity, NASH | Phenotypic Screening (Need Multiple Target Plasmids) |